Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner

Br J Pharmacol. 2011 Aug;163(8):1666-78. doi: 10.1111/j.1476-5381.2010.01146.x.

Abstract

BACKGROUND AND PURPOSE A serine protease, prolyl oligopeptidase (POP) has been reported to be involved in the release of the pro-angiogenic tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Ac-SDKP) from its precursor, 43-mer thymosin β4 (Tβ4). Recently, it was shown that both POP activity and the levels of Ac-SDKP are increased in malignant tumours. The aim of this study was to clarify the release of Ac-SDKP, and test if POP and a POP inhibitor, 4-phenyl-butanoyl-L-prolyl-2(S)-cyanopyrrolidine (KYP-2047), can affect angiogenesis. EXPERIMENTAL APPROACH We used HPLC for bioanalytical and an enzyme immunoassay for pharmacological analysis. Angiogenesis of human umbilical vein endothelial cells was assessed in vitro using a 'tube formation' assay and in vivo using a Matrigel plug assay (BD Biosciences, San Jose, CA, USA) in adult male rats. Moreover, co-localization of POP and blood vessels was studied. KEY RESULTS We showed the sequential hydrolysis of Tβ4: the first-step hydrolysis by proteases to <30-mer peptides is followed by an action of POP. Unexpectedly, POP inhibited the first hydrolysis step, revealing a novel regulation system. POP with Tβ4 significantly induced, while KYP-2047 effectively prevented, angiogenesis in both models compared with Tβ4 addition itself. POP and endothelial cells were abundantly co-localized in vivo. CONCLUSIONS AND IMPLICATIONS We have now revealed that POP is a second-step enzyme in the release of Ac-SDKP from Tβ4, and it has novel autoregulatory effect in the first step. Our results also advocate a role for Ac-SDKP in angiogenesis, and suggest that POP has a pro-angiogenic role via the release of Ac-SDKP from its precursor Tβ4 and POP inhibitors can block this action.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / metabolism
  • Angiogenesis Inhibitors / pharmacology
  • Animals
  • Biocompatible Materials / metabolism
  • Collagen / metabolism
  • Drug Combinations
  • Endothelial Cells / drug effects*
  • Growth Inhibitors / analysis
  • Growth Inhibitors / biosynthesis
  • Humans
  • Kidney / drug effects*
  • Laminin / metabolism
  • Male
  • Neovascularization, Pathologic / metabolism
  • Oligopeptides / analysis
  • Oligopeptides / biosynthesis
  • Proline / analogs & derivatives*
  • Proline / pharmacology
  • Prolyl Oligopeptidases
  • Proteoglycans / metabolism
  • Rats
  • Rats, Inbred WF
  • Serine Endopeptidases / physiology*
  • Serine Proteinase Inhibitors / pharmacology*
  • Thymosin / metabolism
  • Umbilical Veins / drug effects*

Substances

  • 4-phenylbutanoyl-prolylcyanopyrrolidine
  • Angiogenesis Inhibitors
  • Biocompatible Materials
  • Drug Combinations
  • Growth Inhibitors
  • Laminin
  • Oligopeptides
  • Proteoglycans
  • Serine Proteinase Inhibitors
  • matrigel
  • thymosin beta(4)
  • Thymosin
  • Collagen
  • Proline
  • Serine Endopeptidases
  • PREPL protein, human
  • Prolyl Oligopeptidases
  • goralatide